Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, ethylene deltenone, 16ß and 16a me… Read more
Market Cap & Net Worth: Shandong Sito Bio-technology Co Ltd (300583)
Shandong Sito Bio-technology Co Ltd (SHE:300583) has a market capitalization of $382.13 Million (CN¥2.80 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #15636 globally and #4167 in its home market, demonstrating a 1.23% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shandong Sito Bio-technology Co Ltd's stock price CN¥14.78 by its total outstanding shares 189702126 (189.70 Million).
Shandong Sito Bio-technology Co Ltd Market Cap History: 2017 to 2026
Shandong Sito Bio-technology Co Ltd's market capitalization history from 2017 to 2026. Data shows change from $633.65 Million to $382.13 Million (-8.84% CAGR).
Shandong Sito Bio-technology Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shandong Sito Bio-technology Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.52x
Shandong Sito Bio-technology Co Ltd's market cap is 0.52 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $633.65 Million | $785.57 Million | $92.00 Million | 0.81x | 6.89x |
| 2018 | $513.55 Million | $1.05 Billion | $126.85 Million | 0.49x | 4.05x |
| 2019 | $534.04 Million | $965.80 Million | $55.31 Million | 0.55x | 9.66x |
| 2020 | $367.28 Million | $913.19 Million | -$179.81 Million | 0.40x | N/A |
| 2021 | $384.74 Million | $1.20 Billion | $36.21 Million | 0.32x | 10.63x |
| 2022 | $355.51 Million | $1.31 Billion | $41.97 Million | 0.27x | 8.47x |
| 2023 | $494.00 Million | $1.28 Billion | $45.60 Million | 0.39x | 10.83x |
| 2024 | $505.46 Million | $970.60 Million | -$88.77 Million | 0.52x | N/A |
Competitor Companies of 300583 by Market Capitalization
Companies near Shandong Sito Bio-technology Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Shandong Sito Bio-technology Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Shandong Sito Bio-technology Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Shandong Sito Bio-technology Co Ltd's market cap moved from $633.65 Million to $ 382.13 Million, with a yearly change of -8.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥382.13 Million | +7.96% |
| 2025 | CN¥353.95 Million | -29.97% |
| 2024 | CN¥505.46 Million | +2.32% |
| 2023 | CN¥494.00 Million | +38.95% |
| 2022 | CN¥355.51 Million | -7.60% |
| 2021 | CN¥384.74 Million | +4.75% |
| 2020 | CN¥367.28 Million | -31.23% |
| 2019 | CN¥534.04 Million | +3.99% |
| 2018 | CN¥513.55 Million | -18.95% |
| 2017 | CN¥633.65 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Shandong Sito Bio-technology Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $382.13 Million USD |
| MoneyControl | $382.13 Million USD |
| MarketWatch | $382.13 Million USD |
| marketcap.company | $382.13 Million USD |
| Reuters | $382.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.